Clinical Trial

Linperlisib Combined With Chidamide in Patients With PTCL

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The phase Ib part of this study aims to determine the recommended phase II dose （RP2D）of linperlisib in combination with chidamide for the treatment of peripheral T-cell lymphoma (PTCL). The phase IIa part is designed to evaluate the preliminary efficacy and safety of the linperlisib plus chidamide regimen in newly diagnosed PTCL patients. The phase IIb part compares the efficacy and safety of linperlisib combined with chidamide versus the standard CHOP (CHOP-like) regimen in newly diagnosed PTCL patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-14.
Trial Details
NCT Number NCT06421948
Lead Sponsor Yanyan Liu
Conditions Peripheral T-cell Lymphoma
Enrollment 134 participants
Start Date 2024-05-25
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-05